Hu CX, Hu KY, Wang JF. Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study. World J Clin Cases 2020; 8(1): 46-53 [PMID: 31970169 DOI: 10.12998/wjcc.v8.i1.46]
Corresponding Author of This Article
Jian-Feng Wang, MD, Attending Doctor, Department of Pain, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Jinan 250012, Shandong Province, China. 18714779474@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 6, 2020; 8(1): 46-53 Published online Jan 6, 2020. doi: 10.12998/wjcc.v8.i1.46
Potential role of the compound Eucommia bone tonic granules in patients with osteoarthritis and osteonecrosis: A retrospective study
Cheng-Xia Hu, Ke-Yao Hu, Jian-Feng Wang
Cheng-Xia Hu, Department of Pain, Haiyang People’s Hospital, Yantai 265100, Shandong Province, China
Ke-Yao Hu, Department of Urology, Yantaishan Hospital, Yantai 264001, Shandong Province, China
Jian-Feng Wang, Department of Pain, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Author contributions: Hu CX designed and performed the research; Hu KY analyzed the data; Wang JF wrote the paper.
Institutional review board statement: This study was reviewed and approved by the Medical Ethics Committee of Qilu Hospital of Shandong University.
Informed consent statement: All patients in our study provided informed consent.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jian-Feng Wang, MD, Attending Doctor, Department of Pain, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Jinan 250012, Shandong Province, China. 18714779474@163.com
Received: October 28, 2019 Peer-review started: October 28, 2019 First decision: November 13, 2019 Revised: November 19, 2019 Accepted: November 23, 2019 Article in press: November 23, 2019 Published online: January 6, 2020
ARTICLE HIGHLIGHTS
Research background
Osteoarthritis is a multifactorial disease and its occurrence is positively related to age and is the leading cause of disability and pain.
Research motivation
There is currently no effective pharmacological strategy to prevent the development of the disease.
Research objectives
To evaluate the therapeutics of the compound Eucommia bone tonic granules for treating osteoarthritis and osteonecrosis.
Research methods
Patients were separated into two treatment groups: the Eucommia-meloxicam group and the meloxicam group. In addition, the concentrations of bone-GLA protein, interleukin-17, recombinant human S100 calcium binding protein A12, Sphingosine 1-phosphate, cystatin C, creatinine, and hemoglobin were compared before and after treatment. The bone and joint necrosis test and osteonecrosis experiment were carried out to observe the total effective rate of the two groups.
Research results
The combination of Eucommia and meloxicam treatment resulted in improved pain relief and patient satisfaction.
Research conclusions
The combination of Eucommia and meloxicam was an effective and safe drug in the treatment of osteoarthritis and osteonecrosis.
Research perspectives
The patients with osteoarthritis and osteonecrosis will receive benefits from the latest innovations in drug therapies.
